TIG:NGS-TiGenix

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 46.52

Change

0.00 (0.00)%

Market Cap

USD 0.72B

Volume

70.00

Yahoo Analyst Target

USD 31.80 (-31.64%)

STA Analyst Target

N/A
Yahoo Analyst Rating

Verdict

STA Analyst Rating

N/A

STA Verdict

Verdict

About

TiGenix NV is engaged in developing and commercializing novel therapeutics from its r proprietary technology platforms of allogeneic, or donor derived, stem cells.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-07-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

-1.27 (-0.66%)

USD 126.05B
GILD Gilead Sciences Inc.

+0.32 (+0.42%)

USD 100.60B
BIIB Biogen Inc.

+0.60 (+0.17%)

USD 75.69B
CELG Celgene Corporation

-0.24 (-0.28%)

USD 60.15B
SHPG Shire plc

-1.73 (-1.00%)

USD 52.19B
VRTX Vertex Pharmaceuticals Incorpo..

-2.72 (-1.51%)

USD 45.21B
REGN Regeneron Pharmaceuticals Inc.

-0.63 (-0.17%)

USD 39.60B
ALXN Alexion Pharmaceuticals Inc.

+0.07 (+0.05%)

USD 30.07B
BMRN BioMarin Pharmaceutical Inc.

-0.97 (-0.94%)

USD 18.01B
INCY Incyte Corporation

-0.91 (-1.30%)

USD 14.67B

ETFs Containing TIG

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 103.14% 92% A- 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 103.14% 92% A- 96% A
Trailing 12 Months  
Capital Gain 121.31% 85% B 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 121.31% 85% B 95% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 53.55% 85% B 94% A
Dividend Return 53.55% 85% B 94% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 74.72% 30% F 10% F
Risk Adjusted Return 71.67% 94% A 70% C-
Market Capitalization 2.51B 72% C- 62% D-

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.84 20% F 12% F
Price / Cash Flow Ratio -5.95 84% B 91% A-
Price/Free Cash Flow Ratio -13.07 74% C 81% B-
Management Effectiveness  
Return on Equity -219.00% 11% F 5% F
Return on Invested Capital -100.97% 23% F 8% F
Return on Assets -89.13% 19% F 6% F
Debt to Equity Ratio 138.00% 12% F 17% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

TIG:NGS-TiGenix

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 46.52

Change

0.00 (0.00)%

Market Cap

USD 0.72B

Volume

70.00

Yahoo Analyst Target

USD 31.80 (-31.64%)

STA Analyst Target

N/A
Yahoo Analyst Rating

Verdict

STA Analyst Rating

N/A

STA Verdict

Verdict

Values as of: 2018-07-20